The adMare portfolio

Abdera is leveraging its proprietary ROVEr™ platform to engineer and develop new precision radiotherapeutics with tunable PK properties to maximize therapeutic effect while mitigating systemic toxicities in order to treat a broad range of solid tumors.

26 Therapeutics Inc. is a Montréal-based life sciences company developing first-in-class therapies for dry eye disease and meibomian gland disorders, high-prevalence conditions that remain poorly addressed by today’s treatments.

Bright Angel Therapeutics (BAT) is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections.

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as CryptigenTM TSAs, that are broadly shared across multiple patients with the same tumor type. 

Evolved Therapeutics is focused on establishing innovative antibody discovery platforms to enable the discovery of first- and best-in-class therapeutics. 

Find Therapeutics designs ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases. 

Immugenia is an early stage immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses. 

Kainova focuses on breakthrough GPCR-modulating therapies in immuno-oncology and inflammation, built on decades of scientific and medical expertise from our leadership team, and our proprietary, validated approach. We foster a culture where scientific excellence and human purpose go hand in hand.

KisoJi is a privately-held next-generation antibody company developing multi-specific antibodies to improve outcomes in oncology. 

Neurasic Therapeutics is a company created to advance research that aims to provide new opiate-sparing pain-relieving drugs. 

Ocythera develops a compound that is unique, safe, and targets a specific enzyme for treatment of rare bone diseases.

Specific Biologics Inc.’s (SBI) mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body. 

Flosonics Medical is a medical device company focused on developing non-invasive sensors to improve the management of critically-ill patients. 

Thryv Therapeutics Inc. is a precision medicine company developing novel SGK1 inhibitors for Long QT Syndrome and resistant cancers. With $15M in recent financing, the company is advancing proof-of-concept studies and preparing for IND submission. 

Zucara Therapeutics Inc. is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. 

Artelo Biosciences develops innovative therapeutics that modulate lipid-signaling pathways – an emerging approach with the potential to treat chronic conditions for which there are no or limited existing options, including pain, cancer, anxiety, and depression, amongst others. 

Bellus Health is developing BLU-5937, a P2X3 antagonist, to help people with chronic cough and other afferent hypersensitization-related disorders. 

Encycle Therapeutics was created to develop a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. 

Inversago Pharma is a clinical-stage, biotech company aiming to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. 

Kairos Therapeutics was a biopharmaceutical company that developed a proprietary next-generation antibody-drug conjugate platform.

Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing.

Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. 

FORUS Therapeutics is a biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer.